BR112022017530A2 - Derivado de oxadiazol - Google Patents

Derivado de oxadiazol

Info

Publication number
BR112022017530A2
BR112022017530A2 BR112022017530A BR112022017530A BR112022017530A2 BR 112022017530 A2 BR112022017530 A2 BR 112022017530A2 BR 112022017530 A BR112022017530 A BR 112022017530A BR 112022017530 A BR112022017530 A BR 112022017530A BR 112022017530 A2 BR112022017530 A2 BR 112022017530A2
Authority
BR
Brazil
Prior art keywords
oxadiazole derivative
formula
relates
present
epilepsy
Prior art date
Application number
BR112022017530A
Other languages
English (en)
Portuguese (pt)
Inventor
Isobe Yoshiaki
Tanaka Tomoyuki
Miyachi Hirotaka
Original Assignee
Sumitomo Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sumitomo Pharma Co Ltd filed Critical Sumitomo Pharma Co Ltd
Publication of BR112022017530A2 publication Critical patent/BR112022017530A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/12—Antiepileptics; Anticonvulsants for grand-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR112022017530A 2020-03-17 2021-03-16 Derivado de oxadiazol BR112022017530A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2020046138 2020-03-17
PCT/JP2021/010628 WO2021187486A1 (ja) 2020-03-17 2021-03-16 オキサジアゾール誘導体

Publications (1)

Publication Number Publication Date
BR112022017530A2 true BR112022017530A2 (pt) 2022-10-18

Family

ID=77768228

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022017530A BR112022017530A2 (pt) 2020-03-17 2021-03-16 Derivado de oxadiazol

Country Status (16)

Country Link
US (2) US12624011B2 (cg-RX-API-DMAC7.html)
EP (1) EP4122923B1 (cg-RX-API-DMAC7.html)
JP (2) JP7637121B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220154208A (cg-RX-API-DMAC7.html)
CN (1) CN115515943B (cg-RX-API-DMAC7.html)
AU (1) AU2021239631B2 (cg-RX-API-DMAC7.html)
BR (1) BR112022017530A2 (cg-RX-API-DMAC7.html)
CA (1) CA3170273A1 (cg-RX-API-DMAC7.html)
DK (1) DK4122923T3 (cg-RX-API-DMAC7.html)
ES (1) ES3041051T3 (cg-RX-API-DMAC7.html)
FI (1) FI4122923T3 (cg-RX-API-DMAC7.html)
MX (1) MX2022011483A (cg-RX-API-DMAC7.html)
PH (1) PH12022552373A1 (cg-RX-API-DMAC7.html)
PT (1) PT4122923T (cg-RX-API-DMAC7.html)
TW (1) TWI879917B (cg-RX-API-DMAC7.html)
WO (1) WO2021187486A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12624011B2 (en) * 2020-03-17 2026-05-12 Sumitomo Pharma Co., Ltd. Oxadiazole derivative
JP7653399B2 (ja) 2021-09-22 2025-03-28 住友ファーマ株式会社 オキサジアゾール誘導体を含有する医薬組成物

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1227978A (cg-RX-API-DMAC7.html) * 1968-09-13 1971-04-15
TW200715993A (en) 2005-06-15 2007-05-01 Senomyx Inc Bis-aromatic amides and their uses as sweet flavor modifiers, tastants, and taste enhancers
RU2426731C2 (ru) * 2005-12-23 2011-08-20 Ф. Хоффманн-Ля Рош Аг Производные арил-изоксазоло-4-ил-оксадиазола
RU2009127095A (ru) * 2006-12-15 2011-01-20 Эбботт Лэборетриз (Us) Новые оксадиазольные соединения
GB0723814D0 (en) * 2007-12-05 2008-01-16 Glaxo Group Ltd Compounds
JP5746612B2 (ja) * 2008-03-19 2015-07-08 オーリムメッド・ファルマ・インコーポレーテッド 中枢神経系疾患および障害の治療に有効な新規化合物
WO2010017132A1 (en) * 2008-08-04 2010-02-11 Chdi, Inc. Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
US20110224304A1 (en) * 2008-11-14 2011-09-15 Dainippon Sumitomo Pharma Co., Ltd. Biphenylacetamide derivative
JP2012001537A (ja) * 2010-05-19 2012-01-05 Dainippon Sumitomo Pharma Co Ltd ビフェニルアセトアミド誘導体からなる医薬
WO2011145669A1 (ja) * 2010-05-19 2011-11-24 大日本住友製薬株式会社 アミド誘導体
US9199981B2 (en) 2011-09-01 2015-12-01 Novartis Ag Compounds and compositions as C-kit kinase inhibitors
SI2772482T1 (sl) * 2011-10-27 2016-06-30 Taisho Pharmaceutical Co., Ltd. Derivat azola
JP2013221025A (ja) * 2012-04-19 2013-10-28 Dainippon Sumitomo Pharma Co Ltd ビフェニルアセトアミド誘導体の製造方法及びその中間体
WO2014072957A1 (en) * 2012-11-12 2014-05-15 Lupin Limited Thiazole derivatives as alpha 7 nachr modulators
JP6387669B2 (ja) * 2013-04-26 2018-09-12 大正製薬株式会社 アゾール誘導体を含有する医薬
WO2015161014A1 (en) * 2014-04-17 2015-10-22 Merck Sharp & Dohme Corp. Heterocyclic cgrp receptor antagonists
TW201642855A (zh) 2015-03-10 2016-12-16 健臻公司 用於治療蛋白質病變之方法
WO2017066103A1 (en) * 2015-10-16 2017-04-20 Aurimmed Pharma, Inc. Novel compounds advantageous in the treatment of central nervous system diseases and disorders
TW201729807A (zh) * 2015-10-30 2017-09-01 Ptc治療公司 用於治療癲癇的方法
US12624011B2 (en) * 2020-03-17 2026-05-12 Sumitomo Pharma Co., Ltd. Oxadiazole derivative

Also Published As

Publication number Publication date
US12624011B2 (en) 2026-05-12
US20230092498A1 (en) 2023-03-23
US20230265061A1 (en) 2023-08-24
TWI879917B (zh) 2025-04-11
ES3041051T3 (en) 2025-11-06
FI4122923T3 (fi) 2025-11-12
EP4122923A4 (en) 2024-04-24
KR20220154208A (ko) 2022-11-21
DK4122923T3 (da) 2025-12-15
CA3170273A1 (en) 2021-09-23
AU2021239631A8 (en) 2022-12-01
TW202146392A (zh) 2021-12-16
JP2025081449A (ja) 2025-05-27
WO2021187486A1 (ja) 2021-09-23
CN115515943B (zh) 2024-07-09
PH12022552373A1 (en) 2023-12-18
AU2021239631B2 (en) 2026-05-14
PT4122923T (pt) 2025-12-03
JP7637121B2 (ja) 2025-02-27
EP4122923B1 (en) 2025-09-10
CN115515943A (zh) 2022-12-23
EP4122923A1 (en) 2023-01-25
JPWO2021187486A1 (cg-RX-API-DMAC7.html) 2021-09-23
AU2021239631A1 (en) 2022-11-10
US11718592B2 (en) 2023-08-08
MX2022011483A (es) 2022-10-07

Similar Documents

Publication Publication Date Title
ECSP21080528A (es) Compuestos antivirales que contienen nitrilo
JOP20220131A1 (ar) مركبات أمينو كينولون تحمل بدائل تستخدم كمثبطات لـ dgkalpha من أجل تنشيط المناعة
JOP20200154B1 (ar) مركبات ومشتقات بيريدو بيريمينون بها استبدال ببنزيل أمينو جديدة كمثبطات sos1
BR112021009595A2 (pt) Terapia de combinação incluindo um inibidor de krasg12c e um ou mais agentes farmaceuticamente ativos adicionais para o tratamento de cânceres
AR054234A1 (es) Composicion farmaceutica para el tratamiento del cancer
MX2022004451A (es) Heteroaril-bifenil-amidas para el tratamiento de enfermedades relacionadas con el ligando pd-l1.
CL2021002747A1 (es) Agentes antivirales para la hepatitis b (solicitud divisional no. 487-2020)
CL2023000289A1 (es) Combinaciones para el tratamiento de cáncer
BR112012030177A2 (pt) composto, uso do mesmo, e, composição farmacêutica
NI200700064A (es) Nuevas composiciones farmacéuticas que comprenden ácido 4-(4-(3-(4-cloro-3- trifluorometil-fenil)- ureido)-3-fluoro-fenoxi)-piridin-2-carboxílico para el tratamiento de trastornos hiperproliferativos.
AR066063A1 (es) Derivados de triazol que son antagonistas de smo
MX2025003905A (es) Tiosulfato de sodio anhidro y formulaciones de este
PH12020552186A1 (en) Cyanotriazole compounds and uses thereof
MX2024009216A (es) Inhibidores de ectonucleotido pirofosfatasa-fosfodiesterasa 1 (enpp1) y usos de los mismos.
CO2022008616A2 (es) Composición farmacéutica oral que comprende compuesto de carbamato y método de preparación para la misma
JOP20230275A1 (ar) معدلات trex1
MX2025014275A (es) Derivado de pirrolopirimidina y uso del mismo en medicina
PH12022552373A1 (en) Oxadiazole derivative
MX2023014898A (es) Terapia combinada anti-vhc ventajosa.
AR126393A1 (es) Terapia combinada para el tratamiento de enfermedades hepáticas
PE20231943A1 (es) Formulacion combinada oral que incluye gemigliptina y dapagliflozina y metodo de preparacion para la misma
BR112015024897A2 (pt) derivado de fenila
BR112023023965A2 (pt) Método terapêutico para um gato com doença renal crônica, e, agente terapêutico
MX2021014447A (es) Metodos de otoproteccion contra agentes antineoplasicos a base de platino.
MX2024000087A (es) Compuestos tiazol-lactama-espiroheterociclicos y sus aplicaciones.